You are here:
Yervoy
Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma.
No estimate possible yet
Positive CHMP opinion
Ipilimumab
Oncology
Indication extension
Skin cancer
BMS
Intravenous
Intravenous drip
Intermural (MSZ)
Centralised (EMA)
Normal trajectory
No
September 2022
June 2023
Positieve CHMP opinie ontvangen 26 april 2023
< 5
Market share is generally not included unless otherwise stated.
Expertopinie;
Het betreft een indicatie-uitbreiding voor 12-18 jaar. Op basis van een expertopinie wordt er verwacht dat er maximaal 5 patiënten in aanmerking zullen komen voor deze indicatie.
G-standaard
Nivolumab 10mg/ml flacon, 4 ml (40mg): €405,03; Nivolumab 10mg/ml flacon, 10ml (100mg): €1.012,56; Nivolumab 10mg/ml flacon, 24ml (240mg): €2.430,15; Z-index, 1 april 2021, exclusief btw. Prijs is ingeschat in lijn met andere indicaties. Voor alle indicatie van nivolumab geldt een financieel arrangement die is voortgekomen uit de onderhandelingen in de sluis lopend tot 1 januari 2024. Ipilimumab 5mg/ml, flacon 10ML (50mg): €3.268,50; Ipilimumab 5mg/ml, flacon 40ML (200mg): €1.3074. Z-index, 1 april 2021, exclusief btw.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines